Article in ChemMedChem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Valentina Noemi MadiaDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0002-5724-612X
Roberta EmmoloDipartimento di Scienze della Vita e dell'Ambiente Sezione biomedica, Laboratorio di Virologia Molecolare Blocco E, primo piano, Università di Cagliari, Cittadella Universitaria di Monserrato, SS554 -09042, Monserrato (CA), Italia.ORCID http://orcid.org/0009-0009-4546-6449
Elisa PatacchiniDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0002-4531-3612
Stefania MaloccuDipartimento di Scienze della Vita e dell'Ambiente Sezione biomedica, Laboratorio di Virologia Molecolare Blocco E, primo piano, Università di Cagliari, Cittadella Universitaria di Monserrato, SS554 -09042, Monserrato (CA), Italia.
Davide IalongoDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0002-4672-2936
Aurora AlbanoDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0009-0008-6850-528X
Giuseppe RuggieriDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0009-0004-3911-6833
Emanuele CaraDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0009-0008-7723-2201
Laura ZarboDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0009-0009-3724-4133
Antonella MessoreDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0003-0158-5816
Francesca EspositoDipartimento di Scienze della Vita e dell'Ambiente Sezione biomedica, Laboratorio di Virologia Molecolare Blocco E, primo piano, Università di Cagliari, Cittadella Universitaria di Monserrato, SS554 -09042, Monserrato (CA), Italia.ORCID http://orcid.org/0000-0001-9725-7977
Enzo TramontanoDipartimento di Scienze della Vita e dell'Ambiente Sezione biomedica, Laboratorio di Virologia Molecolare Blocco E, primo piano, Università di Cagliari, Cittadella Universitaria di Monserrato, SS554 -09042, Monserrato (CA), Italia.ORCID http://orcid.org/0000-0002-4849-0980
Angela CoronaDipartimento di Scienze della Vita e dell'Ambiente Sezione biomedica, Laboratorio di Virologia Molecolare Blocco E, primo piano, Università di Cagliari, Cittadella Universitaria di Monserrato, SS554 -09042, Monserrato (CA), Italia.ORCID http://orcid.org/0000-0002-6630-8636
Roberto Di SantoDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0002-4279-7666
Roberta CostiDipartimento di Chimica e Tecnologie del Farmaco Istituto Pasteur-Fondazione Cenci Bolognetti, "Sapienza" Università di Roma, p.le Aldo Moro 5, I-00185, Rome, Italy.ORCID http://orcid.org/0000-0002-1314-9029
Funding
EU funding within the Next Generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases Project no. PE00000007, INF-ACT, Spoke 5EU funding within the Next Generation EU-MUR PRIN 2022 20228NPP2YSapienza Università di Roma Ateneo 2023 (project code RM123188EDEF3754)
6 · The paper itself
Abstract
It has been more than four years since the first report of SARS-CoV-2, the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic, the scientific community is focused on vaccine development in an exceptionally rapid time frame, as well as the evaluation of a wide range of potential treatments in clinical trials, a few of which have also reached the market. However, these drugs are characterized by several limits (including low response to treatment in some patients, low effectiveness against the new variants, severe side effects, etc.), thus underscoring the need to speed up the research. Among potential antiviral targets, the SARS-CoV-2 nonstructural protein 13 (nsp13) is highly promising thanks to its pivotal role in viral replication. Pursuing the studies on the development of nsp13 inhibitors, herein, the design, synthesis, and biological evaluation of new SARS-CoV-2 nsp13 inhibitors are reported. In general, the newly designed dikehexenoic derivatives are proven active against both the enzymatic activities showing measurable IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structure-Activity Relationships of New 1-Aryl-1H-Indole Derivatives as SARS-CoV-2 Nsp13 Inhibitors. · full record | OpenQuestion